Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 56, Issue 1, Pages 56-66
Publisher
Wiley
Online
2015-06-19
DOI
10.1002/jcph.566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice
- (2015) M. J. Melchers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
- (2014) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the CeftolozaneIn VivoPharmacokinetic/Pharmacodynamic Target
- (2014) A. J. Lepak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
- (2014) J. A. Roberts et al. CLINICAL INFECTIOUS DISEASES
- Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
- (2014) T W Felton et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
- (2014) David J. Farrell et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
- (2014) Gurudatt Chandorkar et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study
- (2013) Anouk E. Muller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- How should we dose antibiotics for pneumonia in the ICU?
- (2013) Andrew A. Udy et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients
- (2013) Mario Tumbarello et al. INTENSIVE CARE MEDICINE
- Pharmacokinetics of Meropenem in Critically Ill Patients With Severe Infections
- (2013) Lutz Binder et al. THERAPEUTIC DRUG MONITORING
- Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
- (2012) Pratik Bhagunde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
- (2012) W. A. Craig et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
- (2012) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimal Doripenem Dosing Simulations in Critically Ill Nosocomial Pneumonia Patients With Obesity, Augmented Renal Clearance, and Decreased Bacterial Susceptibility*
- (2012) Jason A. Roberts et al. CRITICAL CARE MEDICINE
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia
- (2011) T. P. Lodise et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid
- (2011) Keith A. Rodvold et al. CLINICAL PHARMACOKINETICS
- Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia
- (2010) Ronald N. Jones CLINICAL INFECTIOUS DISEASES
- Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
- (2010) J. Rello et al. EUROPEAN RESPIRATORY JOURNAL
- Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia*
- (2009) Emmanuel Boselli et al. CRITICAL CARE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started